News | Events

Progress Reports 2022

t.b.d.

Date	Projects
February, 4th 13:30 - 15:00 h	P10 (Sommer/Skevaki) P2 (Becker/Herold)
May 6th, 12:00 - 15:00 h	P1 (Bauer/Weber) P3 (Ziebuhr/Kracht) P5 (Vadász/Samakovlis)
Sep 23rd, 12.30 - 15:00 h	P6 (Morty/Friebertshäuser/Ehrhardt) P8 (Herold/Braun)
Nov, 4th, 12.00 - 15:00 h VC	P7 (El Agha/Günther/Bellusci) P10 (Sommer/Skevaki) early career report (Müller) Z1 (Hain/Goesmann/ Wilhelm/Looso)

Ein kleines Protein gegen COVID-19

Download - Pressemitteilung

Gießener Lungenforscherinnen und -forscher testen einen Wirkstoff gegen schwere Verläufe von COVID-19 – BMBF fördert die klinische Studie mit rund 1,84 Millionen Euro

Progress Reports 2021

ECCPS Seminar Room

Aulweg 130

35392 Gießen

Date	Projects
April, 23rd 13:00 - 15:00 h	P10 (Sommer/Skevaki) P1 (Bauer/Weber)
July 2nd, 13:00 - 15:00 h	P2 (Becker/Herold) P3 (Ziebuhr/Kracht)
Sep 3rd, 12.30-15:00 h	P5 (Vadász/Samakovlis) P6 (Morty/Friebertshäuser/Ehrhardt) P7 (El Agha/Günther/Bellusci)
Dec 03rd, 12.30-14:30 h	P8 (Herold/Braun) Z1 (Hain/Goesmann/ Wilhelm/Looso)

GM-CSF study extended to COVID-19 patients

GM-CSF (granulocyte/macrophage colony-stimulating factor) was found to be highly protective in pre-clinical models of pneumonia-associated lung injury including viral infection. There is first evidence of a beneficial effect of inhaled GM-CSF in patients with severe pneumonia/ARDS.
A placebo-controlled, randomized clinical phase II investigator-initiated trial (GI-HOPE, NCT02595060) currently addresses the adjunctive therapeutic role of aerosolized GM-CSF in patients with pneumonia-related ARDS (for further details see project 9). The study was extended to COVID-19 patients, please find the BMBF report here.

Progress Reports 2020

ECCPS Seminar Room
Aulweg 130
35392 Gießen

Date	Projects
Feb, 7th 13:00 - 15:00	P1 (Bauer/Weber) and P2 (Peteranderl/Becker)
May 29th, 13:00 - 15:00	P3 (Ziebuhr/Kracht) and P5 (Vadász/Samakovlis)
Sept 25th, 13:00 - 15:00	P6 (Morty/ Friebertshäuser/Ehrhardt), and P8 (Herold/Braun)
Dec, 18th, 12:30- 14:00	P7 (Günther/Bellusci/El Agha), Z1 (Hain/Goesmann/ Wilhelm/Looso)

Second Funding Period for the KFO309

We are happy to announce that the KFO309 is funded by the DFG for a second funding period without any restriction for the next three years. We have one additional project now - welcome Natascha Sommer and Chrysanthi Skevaki who examnine the role of metabolic changes in T cell responses induced by viral infections that exacerbate COPD and emphysema in their P10 project.

All News / Events